Epigenetic targeting in pancreatic cancer
Cet article passe en revue les travaux récents sur le développement de médicaments ciblant des mécanismes épigénétiques pour le traitement d'un cancer du pancréas
The prognosis of pancreatic cancer patients is very poor, with a 5-year survival of less than 6%. Therefore, there is an urgent need for new therapeutic options in pancreatic cancer. In the past years it became evident that deregulation of epigenetic mechanisms plays an important role in pancreatic carcinogenesis. This review focuses on the exploitation of drugs that alter histone modifications, DNA methylation and microRNA expression as options for the treatment of pancreatic cancer.